Clonal origin of metastatic testicular teratomas

Timothy D. Jones, Mingsheng Wang, Ming Tse Sung, Shaobo Zhang, Thomas Ulbright, John Eble, Stephen D. Beck, Richard Foster, John J. Anagnostou, Clay Conner, Liang Cheng

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: Testicular teratomas in adult patients are histologically diverse tumors that frequently coexist with other germ cell tumor (GCT) components. These mixed GCTs often metastasize to retroperitoneal lymph nodes where multiple GCT elements are frequently present in the same metastatic lesion. Neither the genetic relationships among the different components in metastatic lesions nor the relationships between primary and metastatic GCT components have been elucidated. Experimental Design: We examined metastases from 31 patients who underwent primary retroperitoneal lymph node dissection for metastatic testicular GCT. All patients had metastatic mature teratoma with one or more other GCT components. This study included a total of 72 metastatic GCT components and 16 primary GCT components from 31 patients. Genomic DNA samples from each component were prepared from formalin-fixed, paraffin-embedded tissue sections using laser-assisted microdissection. Loss of heterozygosity (LOH) assays for seven microsatellite polymorphic markers on chromosomes 1p36 (D1S1646), 9p21 (D9S171 and IFNA), 9q21 (D9S303), 13q22-q31 (D13S317), 18q22 (D18S543), and 18q21 (D18S60) were done to assess clonality. Results: Twenty-nine of 31 (94%) cases showed allelic loss in one or more components of the metastatic GCTs. Twenty-nine of 31 mature teratomas showed allelic loss in at least one of seven microsatellite polymorphic markers analyzed. The frequency of allelic loss in informative cases of metastatic mature teratoma was 27% (8 of 30) with D1S1646, 34% (10 of 29) with D9S171, 37% (10 of 27) with IFNA, 27% (8 of 30) with D9S303, 46% (13 of 28) with D13S317, 26% (7 of 27) with D18S543, and 36% (10 of 28) with D18S60. Completely concordant allelic loss patterns between the mature teratoma and all of the other metastatic GCT components were seen in 26 of 29 cases in which the mature teratoma component showed LOH. Nearly identical allelic loss patterns were seen in the three remaining cases. In six cases analyzed, LOH patterns of each metastatic component were compared with each GCT component of the primary testicular tumor. In all six cases, each primary and metastatic component showed an identical pattern of allelic loss. Conclusion: Our data support the common clonal origin of metastatic mature teratomas with other components of metastatic testicular GCTs and with each component of the primary tumor.

Original languageEnglish
Pages (from-to)5377-5383
Number of pages7
JournalClinical Cancer Research
Volume12
Issue number18
DOIs
StatePublished - Sep 15 2006

Fingerprint

Loss of Heterozygosity
Germ Cell and Embryonal Neoplasms
Cellular Structures
Teratoma
Microsatellite Repeats
Testicular Teratoma
Microdissection
Testicular Neoplasms
Lymph Node Excision
Paraffin
Formaldehyde
Neoplasms
Lasers
Research Design
Chromosomes
Lymph Nodes
Neoplasm Metastasis
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clonal origin of metastatic testicular teratomas. / Jones, Timothy D.; Wang, Mingsheng; Sung, Ming Tse; Zhang, Shaobo; Ulbright, Thomas; Eble, John; Beck, Stephen D.; Foster, Richard; Anagnostou, John J.; Conner, Clay; Cheng, Liang.

In: Clinical Cancer Research, Vol. 12, No. 18, 15.09.2006, p. 5377-5383.

Research output: Contribution to journalArticle

Jones, Timothy D. ; Wang, Mingsheng ; Sung, Ming Tse ; Zhang, Shaobo ; Ulbright, Thomas ; Eble, John ; Beck, Stephen D. ; Foster, Richard ; Anagnostou, John J. ; Conner, Clay ; Cheng, Liang. / Clonal origin of metastatic testicular teratomas. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 18. pp. 5377-5383.
@article{7bc657b31a5d4701b307a1057fb91fd5,
title = "Clonal origin of metastatic testicular teratomas",
abstract = "Purpose: Testicular teratomas in adult patients are histologically diverse tumors that frequently coexist with other germ cell tumor (GCT) components. These mixed GCTs often metastasize to retroperitoneal lymph nodes where multiple GCT elements are frequently present in the same metastatic lesion. Neither the genetic relationships among the different components in metastatic lesions nor the relationships between primary and metastatic GCT components have been elucidated. Experimental Design: We examined metastases from 31 patients who underwent primary retroperitoneal lymph node dissection for metastatic testicular GCT. All patients had metastatic mature teratoma with one or more other GCT components. This study included a total of 72 metastatic GCT components and 16 primary GCT components from 31 patients. Genomic DNA samples from each component were prepared from formalin-fixed, paraffin-embedded tissue sections using laser-assisted microdissection. Loss of heterozygosity (LOH) assays for seven microsatellite polymorphic markers on chromosomes 1p36 (D1S1646), 9p21 (D9S171 and IFNA), 9q21 (D9S303), 13q22-q31 (D13S317), 18q22 (D18S543), and 18q21 (D18S60) were done to assess clonality. Results: Twenty-nine of 31 (94{\%}) cases showed allelic loss in one or more components of the metastatic GCTs. Twenty-nine of 31 mature teratomas showed allelic loss in at least one of seven microsatellite polymorphic markers analyzed. The frequency of allelic loss in informative cases of metastatic mature teratoma was 27{\%} (8 of 30) with D1S1646, 34{\%} (10 of 29) with D9S171, 37{\%} (10 of 27) with IFNA, 27{\%} (8 of 30) with D9S303, 46{\%} (13 of 28) with D13S317, 26{\%} (7 of 27) with D18S543, and 36{\%} (10 of 28) with D18S60. Completely concordant allelic loss patterns between the mature teratoma and all of the other metastatic GCT components were seen in 26 of 29 cases in which the mature teratoma component showed LOH. Nearly identical allelic loss patterns were seen in the three remaining cases. In six cases analyzed, LOH patterns of each metastatic component were compared with each GCT component of the primary testicular tumor. In all six cases, each primary and metastatic component showed an identical pattern of allelic loss. Conclusion: Our data support the common clonal origin of metastatic mature teratomas with other components of metastatic testicular GCTs and with each component of the primary tumor.",
author = "Jones, {Timothy D.} and Mingsheng Wang and Sung, {Ming Tse} and Shaobo Zhang and Thomas Ulbright and John Eble and Beck, {Stephen D.} and Richard Foster and Anagnostou, {John J.} and Clay Conner and Liang Cheng",
year = "2006",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-06-0444",
language = "English",
volume = "12",
pages = "5377--5383",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Clonal origin of metastatic testicular teratomas

AU - Jones, Timothy D.

AU - Wang, Mingsheng

AU - Sung, Ming Tse

AU - Zhang, Shaobo

AU - Ulbright, Thomas

AU - Eble, John

AU - Beck, Stephen D.

AU - Foster, Richard

AU - Anagnostou, John J.

AU - Conner, Clay

AU - Cheng, Liang

PY - 2006/9/15

Y1 - 2006/9/15

N2 - Purpose: Testicular teratomas in adult patients are histologically diverse tumors that frequently coexist with other germ cell tumor (GCT) components. These mixed GCTs often metastasize to retroperitoneal lymph nodes where multiple GCT elements are frequently present in the same metastatic lesion. Neither the genetic relationships among the different components in metastatic lesions nor the relationships between primary and metastatic GCT components have been elucidated. Experimental Design: We examined metastases from 31 patients who underwent primary retroperitoneal lymph node dissection for metastatic testicular GCT. All patients had metastatic mature teratoma with one or more other GCT components. This study included a total of 72 metastatic GCT components and 16 primary GCT components from 31 patients. Genomic DNA samples from each component were prepared from formalin-fixed, paraffin-embedded tissue sections using laser-assisted microdissection. Loss of heterozygosity (LOH) assays for seven microsatellite polymorphic markers on chromosomes 1p36 (D1S1646), 9p21 (D9S171 and IFNA), 9q21 (D9S303), 13q22-q31 (D13S317), 18q22 (D18S543), and 18q21 (D18S60) were done to assess clonality. Results: Twenty-nine of 31 (94%) cases showed allelic loss in one or more components of the metastatic GCTs. Twenty-nine of 31 mature teratomas showed allelic loss in at least one of seven microsatellite polymorphic markers analyzed. The frequency of allelic loss in informative cases of metastatic mature teratoma was 27% (8 of 30) with D1S1646, 34% (10 of 29) with D9S171, 37% (10 of 27) with IFNA, 27% (8 of 30) with D9S303, 46% (13 of 28) with D13S317, 26% (7 of 27) with D18S543, and 36% (10 of 28) with D18S60. Completely concordant allelic loss patterns between the mature teratoma and all of the other metastatic GCT components were seen in 26 of 29 cases in which the mature teratoma component showed LOH. Nearly identical allelic loss patterns were seen in the three remaining cases. In six cases analyzed, LOH patterns of each metastatic component were compared with each GCT component of the primary testicular tumor. In all six cases, each primary and metastatic component showed an identical pattern of allelic loss. Conclusion: Our data support the common clonal origin of metastatic mature teratomas with other components of metastatic testicular GCTs and with each component of the primary tumor.

AB - Purpose: Testicular teratomas in adult patients are histologically diverse tumors that frequently coexist with other germ cell tumor (GCT) components. These mixed GCTs often metastasize to retroperitoneal lymph nodes where multiple GCT elements are frequently present in the same metastatic lesion. Neither the genetic relationships among the different components in metastatic lesions nor the relationships between primary and metastatic GCT components have been elucidated. Experimental Design: We examined metastases from 31 patients who underwent primary retroperitoneal lymph node dissection for metastatic testicular GCT. All patients had metastatic mature teratoma with one or more other GCT components. This study included a total of 72 metastatic GCT components and 16 primary GCT components from 31 patients. Genomic DNA samples from each component were prepared from formalin-fixed, paraffin-embedded tissue sections using laser-assisted microdissection. Loss of heterozygosity (LOH) assays for seven microsatellite polymorphic markers on chromosomes 1p36 (D1S1646), 9p21 (D9S171 and IFNA), 9q21 (D9S303), 13q22-q31 (D13S317), 18q22 (D18S543), and 18q21 (D18S60) were done to assess clonality. Results: Twenty-nine of 31 (94%) cases showed allelic loss in one or more components of the metastatic GCTs. Twenty-nine of 31 mature teratomas showed allelic loss in at least one of seven microsatellite polymorphic markers analyzed. The frequency of allelic loss in informative cases of metastatic mature teratoma was 27% (8 of 30) with D1S1646, 34% (10 of 29) with D9S171, 37% (10 of 27) with IFNA, 27% (8 of 30) with D9S303, 46% (13 of 28) with D13S317, 26% (7 of 27) with D18S543, and 36% (10 of 28) with D18S60. Completely concordant allelic loss patterns between the mature teratoma and all of the other metastatic GCT components were seen in 26 of 29 cases in which the mature teratoma component showed LOH. Nearly identical allelic loss patterns were seen in the three remaining cases. In six cases analyzed, LOH patterns of each metastatic component were compared with each GCT component of the primary testicular tumor. In all six cases, each primary and metastatic component showed an identical pattern of allelic loss. Conclusion: Our data support the common clonal origin of metastatic mature teratomas with other components of metastatic testicular GCTs and with each component of the primary tumor.

UR - http://www.scopus.com/inward/record.url?scp=33749341827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749341827&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-0444

DO - 10.1158/1078-0432.CCR-06-0444

M3 - Article

VL - 12

SP - 5377

EP - 5383

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -